Immix Biopharma (IMMX) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 60.7% versus a loss of 65.0%. Janux Therapeutics is the larger company by market cap ($616.7 million vs $583.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | JANX |
|---|---|---|
| Share price | $6.96 | $10.08 |
| Market cap | $583.33M | $616.73M |
| 1-day change | -1.14% | -2.04% |
| YTD return | +33.08% | -26.96% |
| 1-year return | +60.74% | -65.00% |
| 5-year return | — | -42.92% |
| EPS (TTM) | $-0.83 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | -5.55% |
| Net income (latest FY) | $-29.40M | $-113.63M |
| Operating margin | — | -1576.67% |
| Net margin | — | -1136.25% |
| 52-week high | $15.10 | $35.34 |
| 52-week low | $3.78 | $10.05 |
| Distance from 52-week high | -53.91% | -71.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.82% | +228.77% |
| Average volume | 1.45M | 961.56K |
| Shares outstanding | 83.81M | 61.18M |
| Employees | 21 | 114 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed JANX by 125.7 percentage points over the past year.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
IMMX vs JANX FAQ
Which is bigger, Immix Biopharma or Janux Therapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $583.33M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, IMMX or JANX?
IMMX returned +60.74% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Immix Biopharma and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.